Our Journey to Success

As a Stand Alone Company
Developing TWi's own generic and brand product for US market

2015

Launched 2 products in TWi’s own label in US market in March

Increased holding stake in Visum to 66%

Obtained Guanfacine ER Tablet final approval from US FDA and launched the product in US

2014

Obtained final approval of 3 ANDAs from FDA

Established US commercial operations and UK supply chain

Acquired 53% stake in Visum Pharmaceutical Co., China

2013

Publicly listed on Taipei Exchange, stock ticker : 4180

Acquired U-Liang Pharmaceutical, Co.

Selected as "Key Counseling Mittelstand Target" by Taiwan's Industrial Development Bureau, Ministry of Economic Affairs

2012

Began trading on the Emergin Market Board. Stock ticker: 4180

Received approval for stock public issuance

Completed share transfer with TWi Holding to allow the TWi Holdings' shareholders to directly own of TWi Pharmaceuticals' share

Chungli Plant completes PIC/C audit by FDA

2011

Chungli Plant Passed Teva Global Quality System Audit

Completed acquisition of TWi Biotechnology, Inc. as 100% fully-owned subsidiary

2010

Spun out the new drug development division as TWi Biotechnology, Inc. for the development of new drug

Complete corporate restructuring in which TWi Holdings had been separated from Anchen Inc. and become the parent company of TWi Pharmaceuticals, Inc.

As Anchen Inc. Subsidiary
Laying foundation for development of High Barrier Generics

2009

Chungli plant OEM anti-epileptic drugs for Anchen and began exporting to USA‏‏

2007

Chungli plant passed US FDA Pre-Approval Inspection

2006

Completed acquisition of Empax Pharma and changed company name to TWi Pharmaceuticals, Inc.

Founding Period

2004

Acquired Parke-Davis' production facility in Chungli‏

2002

Anchen Inc. established Taiwan subsidiary, TWi Pharmaceuticals, Ltd.

Top